Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00054496|
Recruitment Status : Unknown
Verified December 2006 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : February 6, 2003
Last Update Posted : January 10, 2014
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.
|Condition or disease||Intervention/treatment||Phase|
|Brain and Central Nervous System Tumors||Drug: erlotinib hydrochloride||Phase 2|
- Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib.
- Determine the progression-free and overall survival of patients treated with this drug.
OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||73 participants|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme|
|Study Start Date :||August 2002|
- Response rate
- Progression-free survival
- Overall survival
- Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling
- Efficacy of tumor EGFR amplification in predicting response to treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00054496
|United States, Ohio|
|Cleveland Clinic Taussig Cancer Center||Recruiting|
|Cleveland, Ohio, United States, 44195|
|Contact: Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100|
|Study Chair:||Michael A. Vogelbaum, MD, PhD||The Cleveland Clinic|